Opinion|Videos|March 24, 2025
The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis
Experts discuss the clinical and economic burden of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis in the US, exploring their impact on health care systems, the importance of prevention in reducing this burden, and the challenges of implementing preventive strategies, while considering the potential benefits of improved risk assessment and prevention in the ASCVD space.
Advertisement
Video content above is prompted by the following:
- Please describe the clinical and economic burden of atherosclerotic cardiovascular disease—or ASCVD—and aortic stenosis in the US today.
- How do these diseases impact health systems like the ones you work with?
- What role does prevention play in mitigating this burden?
- Adherence to preventive regimens can be difficult for patients. On a population level, do the challenges of implementing preventive ASCVD strategies outweigh the benefits? Is there a place for better risk assessment and prevention in the ASCVD space?
Advertisement
Related to this article
In this Q&A, Christie Ballantyne, MD, explains why consistent LDL-C lowering with oral enlicitide could expand PCSK9 use in primary prevention.
Independent VESALIUS-CV analysis finds evolocumab cost-effective at about 36% below the ACC/AHA benchmark for patients without prior MI or stroke.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
New analyses from VESALIUS-CV and the FOURIER open-label extension add stroke and long-term outcome data for evolocumab.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
AHIP's Jeanette Thornton on Prior Authorization Reform, Midterms
3
US Measles Outbreaks Cost Nearly $83 Million in 2026
4
The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH Costs
5